Scholarlink

<p>The ubiquitin–proteasome system (UPS) is an important regulator of numerous cellular pathways, including DNA repair, protein degradation, the cell cycle, and signal transduction. UBE2C, a member of the ubiquitin-conjugating enzyme family, facilitates the ubiquitination of essential cellular regulators. Notably, UBE2C is consistently overexpressed in breast, lung, brain, hepatocellular, and ovarian carcinomas. Increased UBE2C expression is associated with tumour aggressiveness, genomic instability, epithelial-to-mesenchymal transition, and resistance to chemotherapy and radiotherapy. Our review explores the mechanistic involvement of UBE2C in diverse cancers, with a particular focus on its involvement in DNA damage repair mediated by the anaphase-promoting complex (APC/C). Furthermore, the regulatory effects of miR-381, miR-503, and miR-205 on UBE2C expression were examined, highlighting the promising prospects of these miRNAs for targeted cancer therapy. The involvement of UBE2C in different cancer hallmarks underscores its potential as a biomarker and therapeutic target. A comprehensive understanding of its mechanistic involvement in cell cycle regulation and DNA repair will further enhance its application in diagnostics, personalised medicine, and precision medicine.</p> Graphical Abstract <p>UBE2C acts as a central regulator of tumour progression by coordinating cell-cycle control, oncogenic signalling, DNA damage repair, and therapy resistance. Dysregulated UBE2C expression promotes cancer cell proliferation, survival, genome maintenance, and treatment resistance, whereas its inhibition through miRNAs, RNAi, or pharmacological agents induces cell-cycle arrest, apoptosis, and enhanced therapeutic sensitivity, supporting UBE2C as an attractive target for cancer therapy. Created with BioRender.com.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

UBE2C at the crossroads of cell cycle regulation and DNA damage response in cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Sayandrila Paul,
  • Amoolya Kandettu,
  • Sanjiban Chakrabarty

摘要

The ubiquitin–proteasome system (UPS) is an important regulator of numerous cellular pathways, including DNA repair, protein degradation, the cell cycle, and signal transduction. UBE2C, a member of the ubiquitin-conjugating enzyme family, facilitates the ubiquitination of essential cellular regulators. Notably, UBE2C is consistently overexpressed in breast, lung, brain, hepatocellular, and ovarian carcinomas. Increased UBE2C expression is associated with tumour aggressiveness, genomic instability, epithelial-to-mesenchymal transition, and resistance to chemotherapy and radiotherapy. Our review explores the mechanistic involvement of UBE2C in diverse cancers, with a particular focus on its involvement in DNA damage repair mediated by the anaphase-promoting complex (APC/C). Furthermore, the regulatory effects of miR-381, miR-503, and miR-205 on UBE2C expression were examined, highlighting the promising prospects of these miRNAs for targeted cancer therapy. The involvement of UBE2C in different cancer hallmarks underscores its potential as a biomarker and therapeutic target. A comprehensive understanding of its mechanistic involvement in cell cycle regulation and DNA repair will further enhance its application in diagnostics, personalised medicine, and precision medicine.

Graphical Abstract

UBE2C acts as a central regulator of tumour progression by coordinating cell-cycle control, oncogenic signalling, DNA damage repair, and therapy resistance. Dysregulated UBE2C expression promotes cancer cell proliferation, survival, genome maintenance, and treatment resistance, whereas its inhibition through miRNAs, RNAi, or pharmacological agents induces cell-cycle arrest, apoptosis, and enhanced therapeutic sensitivity, supporting UBE2C as an attractive target for cancer therapy. Created with BioRender.com.